Devextinetug

迪维奈塔单抗

Report date: 2026/03/09 20:02:04

Base Information

Drug NameDevextinetug
Drug Alias NameMETHmAbIXTm-200Ch-mAb7F9
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionImmunomodulatorsAnti-methamphetamine
TargetsMethamphetamine
Therapy Area/IndicationsSubstance-Related DisordersDrug-Related Side Effects and Adverse Reactions
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Arkansas For Medical Sciences
China Registration ClassN/A

Develop Information

Active CompaniesIntervexion Therapeutics Llc
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsSubstance-Related DisordersDrug-Related Side Effects and Adverse Reactions

Other Information

ATC CodeN/A
Related LinksN/A